Hemant Surgical Industries Reports 31.5% Revenue Growth in H1 FY2026, Raises ₹61.53 Crore Through Share Issuance

Hemant Surgical Industries Limited (ISIN: INE0GYI01028) has announced its unaudited financial results for the half year ended September 30, 2025, showcasing significant growth and strategic capital raising initiatives.

Financial Highlights

Revenue Growth: The company reported revenue from operations of ₹64.26 crore for H1 FY2026, marking a 31.5% increase from ₹48.87 crore in the corresponding period of the previous year.
Profitability: Basic earnings per share (EPS) stood at ₹5.09, up from ₹3.05 in the prior year period, indicating improved profitability.

Capital Raising and Utilization

Hemant Surgical Industries has successfully raised ₹61.53 crore through a preferential allotment, comprising:

25,98,400 equity shares at ₹197 per share
20,99,200 convertible warrants

The total proceeds, including the full conversion of warrants, are allocated as follows:

Purpose	Amount (₹ in crore)
Capital expenditure for new facilities and expansion	50.00
Augmenting working capital	15.00
Debt repayment	17.00
General corporate purposes	10.54
Total	92.54

As of September 30, 2025, the company has utilized ₹15.43 crore of the raised funds. The remaining ₹46.09 crore is held in bank accounts, with an additional ₹31.02 crore expected from warrant holders upon conversion.

Operational Performance

The company's strong revenue growth suggests improved market demand for its products. The significant increase in EPS indicates enhanced operational efficiency and cost management.

Future Outlook

With the recent capital infusion, Hemant Surgical Industries is well-positioned to execute its expansion plans. The allocation of funds towards new facilities, working capital, and debt repayment is expected to strengthen the company's operational capabilities and financial position.

Management Commentary

While specific management comments were not provided, the strategic allocation of funds towards expansion and working capital suggests a focus on growth and operational enhancement.

Investors and stakeholders will likely be watching closely to see how effectively the company deploys its newly raised capital to drive future growth and maintain its positive momentum in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.07%	+2.07%	-4.36%	+188.78%	+101.98%	+64.86%

Hemant Surgical Industries Limited , a prominent player in the surgical equipment sector, has made a significant move to strengthen its promoter holding through a preferential allotment of convertible warrants. The company's board has approved the issuance of 600,000 warrants to its promoters and promoter group, a decision that could potentially increase the promoter stake in the company.

Key Details of the Warrant Allotment

Number of Warrants: 600,000
Beneficiaries: Three promoters received an equal distribution of warrants
- Hanskumar Shamji Shah: 200,000 warrants
- Hemant Praful Shah: 200,000 warrants
- Kaushik Hanskumar Shah: 200,000 warrants
Conversion Ratio: Each warrant is convertible into one fully paid-up equity share
Face Value: Rs. 10 per equity share
Conversion Period: Within 18 months from the date of allotment

Impact on Shareholding Structure

The allotment of these warrants has led to a notable change in the company's shareholding pattern:

Metric	Value
Pre-Allotment Promoter Holding	7,680,000 shares (73.56% of total voting capital)
Post-Allotment Promoter Holding	8,680,000 shares (64.67% of total voting capital)
Equity Share Capital Post-Acquisition	Rs. 13,03,84,000 (1,30,38,400 equity shares)
Total Diluted Share Capital	Rs. 15,13,76,000 (1,51,37,600 equity shares)

Regulatory Compliance

In compliance with SEBI regulations, Hemant Surgical Industries has made the necessary disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Implications for Investors

This move by Hemant Surgical Industries signals a strong vote of confidence from the promoter group in the company's future prospects. The increased promoter stake, upon full conversion of the warrants, could potentially align management interests more closely with those of other shareholders.

However, investors should note that the conversion of these warrants will lead to equity dilution, which might have an impact on earnings per share in the short term. The long-term effects will depend on how effectively the company utilizes any additional capital raised through this allotment.

As the surgical equipment industry continues to evolve, Hemant Surgical Industries' strategic decisions, including this preferential allotment, will be crucial in determining its market position and financial performance in the coming years.